Seek Returns

RPRX vs. SNY: Royalty Pharma vs. Sanofi Stock Comparison

How do Royalty Pharma (RPRX) and Sanofi (SNY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Royalty Pharma (RPRX) and Sanofi (SNY) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Sanofi (SNY) has more than two decades of public-market history since July 1, 2002, whereas Royalty Pharma (RPRX) listed on June 16, 2020 and has a much shorter record to draw on.

Royalty Pharma (RPRX) trades as ordinary local shares, while Sanofi (SNY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for Royalty Pharma (RPRX) and Sanofi (SNY)
Profile ItemRPRXSNY
NameRoyalty Pharma plc Class A Ordinary SharesSanofi ADR
Country/RegionUnited StatesFrance
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticalsPharmaceuticals
GICS Sub-IndustryPharmaceuticalsPharmaceuticals
Market Capitalization38.70 billion USD112.71 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJune 16, 2020July 1, 2002
Security TypeCommon StockADR

Price Performance

Cumulative Growth

RPRX
SNY
GSPC
Loading price history…
Royalty Pharma (RPRX) vs. Sanofi (SNY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Royalty Pharma (RPRX) and Sanofi (SNY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Royalty Pharma (RPRX) and Sanofi (SNY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Royalty Pharma (RPRX) and Sanofi (SNY)
MetricRPRXSNY
Total Return (1Y)81.08%2.73%
Total Return (3Y, Annualized)39.21%6.89%
Total Return (5Y, Annualized)14.22%3.16%

Risk Profile

Drawdown History

RPRX
SNY
GSPC
Loading price history…
Royalty Pharma (RPRX) vs. Sanofi (SNY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Royalty Pharma (RPRX) and Sanofi (SNY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Royalty Pharma (RPRX) and Sanofi (SNY)
MetricRPRXSNY
Volatility (1Y, Annualized)22.05%23.60%
Beta (5Y)0.360.28
Max Drawdown (5Y)-41.98%-33.52%
Avg. Volume (3M)3.10M3.29M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
RPRX and SNY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Royalty Pharma (RPRX) and Sanofi (SNY)
MetricRPRXSNY
Sharpe Ratio (1Y)3.48-0.07
Sortino Ratio (1Y)5.72-0.10

Profitability

ROE (TTM)

Royalty Pharma (RPRX) at 12.09% sits in the top ROE quartile, while Sanofi (SNY) at 5.72% is closer to the peer norm — stronger capital efficiency for RPRX.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.09%

Max
109.18%
RPRX
12.09%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.72%

Max
109.18%
Q3
6.23%
SNY
5.72%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Royalty Pharma (RPRX) vs. Sanofi (SNY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Royalty Pharma (RPRX) at 25.70% keeps the most of each sales dollar — above its industry’s net margin range — and Sanofi (SNY) at 8.20% also retains a top-quartile share.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.70%

RPRX
25.70%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.20%

Max
18.05%
SNY
8.20%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Royalty Pharma (RPRX) vs. Sanofi (SNY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Royalty Pharma (RPRX) at 81.32% and Sanofi (SNY) at 30.89% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

81.32%

Max
83.12%
RPRX
81.32%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.89%

Max
83.12%
SNY
30.89%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Royalty Pharma (RPRX) vs. Sanofi (SNY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Royalty Pharma (RPRX) and Sanofi (SNY)
MetricRPRXSNY
ROE (TTM)12.09%5.72%
ROA (TTM)5.43%5.31%
Net Margin (TTM)25.70%8.20%
Operating Margin (TTM)81.32%30.89%
Gross Margin (TTM)99.79%73.68%

Growth

Revenue Growth

Both Royalty Pharma (RPRX) at 5.06% and Sanofi (SNY) at 5.49% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Royalty Pharma (RPRX) vs. Sanofi (SNY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Royalty Pharma (RPRX) at 23.09% and Sanofi (SNY) at 39.43% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
Royalty Pharma (RPRX) vs. Sanofi (SNY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Royalty Pharma (RPRX) and Sanofi (SNY)
MetricRPRXSNY
Revenue Growth (YoY)5.06%5.49%
Revenue Growth (3Y CAGR)2.06%4.82%
EPS Growth (YoY)23.09%39.43%
EPS Growth (3Y CAGR)161.10%6.02%

Financial Strength

Current Ratio (MRQ)

Both Royalty Pharma (RPRX) at 1.29 and Sanofi (SNY) at 1.12 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.29

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
RPRX
1.29
Min
0.10

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.12

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
SNY
1.12
Min
0.10
Loading chart…
Royalty Pharma (RPRX) vs. Sanofi (SNY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Sanofi (SNY) at 0.27 carries an industry-typical debt-to-equity mix, while Royalty Pharma (RPRX) at 0.88 uses more debt funding than most peers.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.88

Max
1.42
RPRX
0.88
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.27

Max
1.42
Q3
0.65
SNY
0.27
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Royalty Pharma (RPRX) vs. Sanofi (SNY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Royalty Pharma (RPRX) and Sanofi (SNY)
MetricRPRXSNY
Current Ratio (MRQ)1.291.12
Debt / Equity (MRQ)0.880.27
Net Debt / EBITDA4.760.96

Dividends

Dividend Yield (TTM)

Sanofi (SNY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a yield of 1.37%, ranking against industry peers normally.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.37%

RPRX
1.37%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

SNY
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Royalty Pharma (RPRX) vs. Sanofi (SNY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Royalty Pharma (RPRX) reports 60.46%, ranking against industry peers normally.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

60.46%

RPRX
60.46%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

119.86%

SNY
119.86%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Royalty Pharma (RPRX) vs. Sanofi (SNY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Royalty Pharma (RPRX) and Sanofi (SNY)
MetricRPRXSNY
Dividend Yield (TTM)1.37%0.00%
Dividend Payout Ratio (TTM)60.46%119.86%

Valuation

P/E Ratio (TTM)

Sanofi (SNY) at 23.40 is near its industry’s usual P/E ratio, while Royalty Pharma (RPRX) at 43.99 sits in the richer quartile — RPRX needs stronger growth or earnings quality to justify the premium.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.99

Max
85.34
RPRX
43.99
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.40

Max
85.34
Q3
43.46
Median
26.69
SNY
23.40
Q1
13.30
Min
0.07
Loading chart…
Royalty Pharma (RPRX) vs. Sanofi (SNY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Sanofi (SNY) at 2.21 sits in the cheaper P/S ratio quartile while Royalty Pharma (RPRX) at 14.79 prices around its industry’s middle — SNY costs less per dollar of sales, though read it alongside growth and margins.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.79

Max
58.18
Q3
25.77
RPRX
14.79
Median
7.30
Q1
3.01
Min
0.01

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.21

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
SNY
2.21
Min
0.01
Loading chart…
Royalty Pharma (RPRX) vs. Sanofi (SNY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Sanofi (SNY) at 1.38 sits in the lower P/B ratio quartile against book while Royalty Pharma (RPRX) at 4.39 is valued near its industry’s middle — SNY is cheaper on assets, though weigh it against ROE and asset quality.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.39

Max
13.53
Q3
6.54
RPRX
4.39
Median
3.25
Q1
1.69
Min
-5.59

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
SNY
1.38
Min
-5.59
Loading chart…
Royalty Pharma (RPRX) vs. Sanofi (SNY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Royalty Pharma (RPRX) and Sanofi (SNY)
MetricRPRXSNY
P/E Ratio (TTM)43.9923.40
P/S Ratio (TTM)14.792.21
P/B Ratio (MRQ)4.391.38
Free Cash Flow Yield (TTM)-1.16%7.17%